Medincell SA has reported its consolidated annual financial results for the fiscal year ending March 31, 2025. The company achieved revenues of €25.4 million, marking a significant increase of 2.8 times compared to the previous year. Total income, including other income of €2.3 million, amounted to €27.7 million. Operating expenses rose by 17% to €38.5 million. The operating result showed a 48% year-over-year improvement, recording a loss of €10.8 million. The net result also improved by 26% to a loss of €18.4 million. The net financial loss increased to €7.4 million from €4.0 million the previous year, attributed mainly to a €3.5 million non-cash fair value adjustment of warrants put option granted to the EIB, due to the increase in company stock price. Medincell's cash position at the end of the fiscal year included €59.0 million in cash and cash equivalents, and €12.9 million in low-risk financial investments, totaling €71.9 million. The company benefitted from a positive net cash flow from operating activities, driven by a $35 million upfront payment from a partnership with AbbVie and increased royalties from UZEDY® net sales, despite slightly higher operating expenses. There was also an increase in net cash flow from investing activities due to higher financial income from cash deposits. Medincell's CEO, Christophe Douat, highlighted 2024 as a significant year, but further details on the outlook or guidance for the future periods were not provided in the release.